News

LAL Deficiency is a serious, under-diagnosed disease with significant morbidity and early mortality. A rolling submission enables completed portions of the application to be submitted and reviewed on

Fycompa is an oral medication and is the first FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor antagonist. Perampanel CIII was approved by the FDA in October 2012 and

The two firms have also entered into a research collaboration for the discovery of next generation IDO/TDO compounds. As part of the deal, NewLink will receive $150m in

The US-based company has also agreed to carry out human clinical trials using its HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1) in the region. With

The DODAC recommendation is based on the safety and efficacy outcomes from ten psoriasis Phase II/III clinical trials which included nearly 4,000 patients with moderate-to-severe plaque psoriasis. Novartis

The company is focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3

Hyqvia consists of Immune Globulin Infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase developed by Halozyme. The immune globulin treatment for PI in adults was approved by

Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493

RNS60 is a therapeutic saline containing highly potent charge-stabilized nanostructures (CSNs) that decrease inflammation and cell death. Revalesio demonstrated the ability of RNS60 to reduce the inflammatory responses